Pacific Biosciences
PACB
130 hedge funds and large institutions have $491M invested in Pacific Biosciences in 2016 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 58 increasing their positions, 34 reducing their positions, and 15 closing their positions.
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
71% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 34
9% more funds holding
Funds holding: 119 → 130 (+11)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
11% less call options, than puts
Call options by funds: $5.45M | Put options by funds: $6.16M
28% less capital invested
Capital invested by funds: $687M → $491M (-$195M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$30M |
| 2 |
BM
Bridger Management
New York
|
+$19.1M |
| 3 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$9.34M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.89M |
| 5 |
TA
Teachers Advisors
New York
|
+$4.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$18.2M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$9.65M |
| 3 |
Renaissance Technologies
New York
|
-$3.91M |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$3.39M |
| 5 |
Morgan Stanley
New York
|
-$2.79M |
PACB Hedge Fund Activity: Q1 2016 in Review
130 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2016, worth a combined $491M — down 28% from $687M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new PACB positions and 15 closed out — a net gain of 12 holders — while 58 added to existing stakes and 34 trimmed.
The largest buyer was Millennium Management, adding an estimated $30M. The largest seller was Deerfield Management, exiting entirely with an estimated $18.2M sold.
- 130 institutional investors held Pacific Biosciences (PACB) as of Q1 2016, up from 119 in Q4 2015.
- Funds reported $491M of Pacific Biosciences stock for Q1 2016, down 28% quarter-over-quarter.
- 27 funds opened new Pacific Biosciences positions in Q1 2016 and 15 closed out, a net change of +12 holders.
- The largest Pacific Biosciences buyer in Q1 2016 was Millennium Management, an estimated $30M added.
- The largest Pacific Biosciences seller in Q1 2016 was Deerfield Management, an estimated $18.2M sold.
Based on aggregated 13F filings for Q1 2016.